PBD Vivoryon Therapeutics AG

Vivoryon Therapeutics Successfully Completes Private Placement Raising EUR 25 Million

Vivoryon Therapeutics Successfully Completes Private Placement Raising EUR 25 Million

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR FORM AN OFFER FOR SALE OF, OR THE SOLICITATION OF AN OFFER TO BUY, THE SECURITIES REFERRED TO HEREIN IN ANY JURISDICTION, INCLUDING THE UNITED STATES, CANADA, AUSTRALIA, SOUTH AFRICA, JAPAN OR ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW.



Vivoryon Therapeutics Successfully Completes Private Placement Raising EUR 25 Million



To access the press release, please click .









EN
26/05/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vivoryon Therapeutics AG

 PRESS RELEASE

Vivoryon Therapeutics N.V. Reports Full Year 2024 Financial Results an...

Vivoryon Therapeutics N.V. Reports Full Year 2024 Financial Results and Provides Business Update Vivoryon Therapeutics N.V. Reports Full Year 2024 Financial Results and Provides Business Update Successful strategic shift towards a focus on inflammatory and fibrotic diseases, in particular on kidney diseaseVaroglutamstat Phase 2 program shows highly consistent, statistically significant and clinically meaningful improvement of kidney function (eGFR) versus placebo in two independent randomized double-blind placebo-controlled studiesStatistical evidence from meta-analysis of VIVIAD and VIVA-...

 PRESS RELEASE

Vivoryon Therapeutics N.V. Signs Financing Agreement for up to EUR 15 ...

Vivoryon Therapeutics N.V. Signs Financing Agreement for up to EUR 15 Million Vivoryon Therapeutics N.V. Signs Financing Agreementfor up to EUR 15 Million Halle (Saale) / Munich, Germany, April 24, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (“Vivoryon” or the “Company”), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that it has entered into a Standby Equity Purchase Agreement (“SEPA”) of up to EUR 15 million, with Yorkvill...

 PRESS RELEASE

Vivoryon Therapeutics N.V. to Report Full Year 2024 Financial Results ...

Vivoryon Therapeutics N.V. to Report Full Year 2024 Financial Results and Operational Progress on April 29, 2025 Vivoryon Therapeutics N.V. to Report Full Year 2024 Financial Results and Operational Progress on April 29, 2025 Halle (Saale) / Munich, Germany, April 17, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that it will publish its financial results for the full ...

 PRESS RELEASE

Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Update w...

Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Update with KOL Speakers Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Update with KOL Speakers Halle (Saale) / Munich, Germany, February 19, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced key takeaways from its virtual R&D update with KOL (Key Opinion Leader) speakers held February 18, 2025. ...

 PRESS RELEASE

Vivoryon Therapeutics N.V. to Host Virtual R&D Update with KOL Speaker...

Vivoryon Therapeutics N.V. to Host Virtual R&D Update with KOL Speakers on February 18, 2025 Vivoryon Therapeutics N.V. to Host Virtual R&D Update with KOL Speakers on February 18, 2025 Halle (Saale) / Munich, Germany, February 11, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced to host a virtual R&D update with KOL (Key Opinion Leader) speakers on February 18, 2025. ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch